93 related articles for article (PubMed ID: 1313269)
1. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.
Kambayashi J; Watase M; Kawasaki T; Shiba E; Sakon M; Mori T; Isaka Y; Kimura K; Kamada T
Adv Second Messenger Phosphoprotein Res; 1992; 25():383-93. PubMed ID: 1313269
[No Abstract] [Full Text] [Related]
2. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
[TBL] [Abstract][Full Text] [Related]
3. DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin E1 and prostacyclin in four platelet "function" tests.
O'Brien JR; Etherington MD; Salmon GP
Thromb Res; 1988 Apr; 50(1):237-41. PubMed ID: 2840751
[No Abstract] [Full Text] [Related]
4. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
Ashida S; Sakuma K
Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
[No Abstract] [Full Text] [Related]
5. [The mode of action and clinical applications of phosphodiesterase inhibitors as anti-platelet drugs].
Murohara Y; Takatsu Y; Yui Y; Kawai C
Nihon Rinsho; 1989 Apr; 47(4):935-9. PubMed ID: 2545947
[No Abstract] [Full Text] [Related]
6. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
Gray SJ; Heptinstall S
Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
[TBL] [Abstract][Full Text] [Related]
7. CC-1088 Celgene.
Dredge K
Curr Opin Investig Drugs; 2005 May; 6(5):513-7. PubMed ID: 15912966
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
Gillespie E
Biochem Pharmacol; 1988 Jul; 37(14):2866-8. PubMed ID: 2456068
[No Abstract] [Full Text] [Related]
9. Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.
Charpiot B; Brun J; Donze I; Naef R; Stefani M; Mueller T
Bioorg Med Chem Lett; 1998 Oct; 8(20):2891-6. PubMed ID: 9873643
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings].
Follath F; Kersting F; Lewis GR; Dollery CT
Br J Clin Pharmacol; 1975 Aug; 2(4):372P-373P. PubMed ID: 184804
[No Abstract] [Full Text] [Related]
11. Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium.
Tohgo A; Tanaka NG; Osada Y
Invasion Metastasis; 1990; 10(1):1-17. PubMed ID: 2154413
[TBL] [Abstract][Full Text] [Related]
12. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
[TBL] [Abstract][Full Text] [Related]
13. QSAR study of phosphodiesterase inhibitory activity of imidazo[2,1-b]-quinazolines: active site analysis.
Prabhakar YS
Drug Des Deliv; 1989 Dec; 5(2):81-91. PubMed ID: 2577989
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site.
Roma G; Di Braccio M; Grossi G; Piras D; Leoncini G; Bruzzese D; Signorello MG; Fossa P; Mosti L
J Med Chem; 2007 Jun; 50(12):2886-95. PubMed ID: 17500510
[TBL] [Abstract][Full Text] [Related]
15. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
Nakamura K; Ikomi F; Ohhashi T
J Vasc Res; 2006; 43(1):86-94. PubMed ID: 16286783
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).
O'Donnell JM; Zhang HT
Trends Pharmacol Sci; 2004 Mar; 25(3):158-63. PubMed ID: 15019272
[No Abstract] [Full Text] [Related]
18. Inhibitory action of cilostazol, a phosphodiesterase III inhibitor, on catecholamine secretion from cultured bovine adrenal chromaffin cells.
Azuma M; Houchi H; Mizuta M; Kinoshita M; Teraoka K; Minakuchi K
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S29-32. PubMed ID: 12688393
[TBL] [Abstract][Full Text] [Related]
19. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells.
Nishio Y; Kashiwagi A; Takahara N; Hidaka H; Kikkawa R
Horm Metab Res; 1997 Oct; 29(10):491-5. PubMed ID: 9405974
[TBL] [Abstract][Full Text] [Related]
20. Cyclic AMP phosphodiesterase inhibition by coumarins and furanocoumarins.
Sardari S; Nishibe S; Horita K; Nikaido T; Daneshtalab M
Pharmazie; 1999 Jul; 54(7):554-6. PubMed ID: 10445247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
